glp 1 discontinuation Medscape Only one in 12 remain
Description
Patients who lose 50 pounds or more almost universally experience some degree of skin laxity, particularly in areas like the abdomen, arms, thighs, and chest
The FDA approved Ozempic as an insulin-boosting treatment for Type 2 diabetes in 2017
Significant weight loss may alter levothyroxine requirements, necessitating thyroid function tests 6-8 weeks after starting GLP-1 therapy and after substantial weight changes
Other patients are filing lawsuits for other harms resulting from Ozempic
They provide quick energy and require little chewing
